Topics

Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas

2019-10-16 10:39:25 | BioPortfolio

Summary

To assess the efficacy and safety of Temozolomide for second-line treatment of Neuroendocrine Carcinomas progressing after first-line Platinum-based therapy.

Study Design

Conditions

Neuroendocrine Carcinomas

Intervention

Temozolomide

Location

Istituto Tumori di Napoli - Fondazione G. Pascale
Napoli
Campania
Italy
80131

Status

Completed

Source

National Cancer Institute, Naples

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-10-16T10:39:25-0400

Clinical Trials [791 Associated Clinical Trials listed on BioPortfolio]

CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

This is a randomized phase II non comparative study. Patients with metastatic Neuroendocrine Carcinomas (NEC) Grade 3, will be enrolled in the study and will be randomly assigned to receiv...

Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery

This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin and etoposide in treating patients with neuroendocrine carc...

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

The purpose of this study is evaluate the efficacy and safety of FOLFIRINOX in patients with gastroenteropancreatic high-grade neuroendocrine carcinomas. This is a prospective Phase II op...

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors. Drugs used in ch...

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

The purpose of the study is to understand the extent and degree of somatostatin receptor expression in poorly differentiated neuroendocrine carcinomas . This may help to make a determinati...

PubMed Articles [916 Associated PubMed Articles listed on BioPortfolio]

Authors' response to the letter "Temozolomide-Capecitabine (TemCap) chemotherapy for Neuroendocrine Neoplasms (NENs): the dilemma of treatment duration" by Lamarca et al. regarding the original manuscript "Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms."

n/a, this is a response to a letter to the editor.

Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms.

Capecitabine and temozolomide combination (CAPTEM) is associated with high response rates in patients with advanced neuroendocrine neoplasms (NENs). We evaluated the real-world activity and safety of ...

SATB2 in Neuroendocrine Neoplasms: Strong Expression is Restricted to Well-Differentiated Tumors of Lower Gastrointestinal Tract Origin and is More Frequent in Merkel Cell Carcinoma among Poorly Differentiated Carcinomas.

Special AT-rich sequence-binding protein 2 (SATB2) is a transcriptional regulator with critical roles in brain, craniofacial, and skeletal development. It has emerged as a key marker of lower gastroin...

Primary neuroendocrine carcinoma of the breast: a 5-year experiences.

Breast neuroendocrine carcinomas constitute approximately 0.3-0.5% of all breast cancers. In this study, we aimed to evaluate the data of patients diagnosed with primary breast neuroendocrine carcinom...

Gastric mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) with pancreatic acinar differentiation: a case report.

Gastric mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) are infrequently encountered in routine practice. Some gastric neuroendocrine carcinomas (NECs) have a variety of differentiation pat...

Medical and Biotech [MESH] Definitions

A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)

A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)

Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.

A 38-kDa integral membrane glycoprotein of the presynaptic vesicles in neuron and neuroendocrine cells. It is expressed by a variety of normal and neoplastic neuroendocrine cells and is therefore used as an immunocytochemical marker for neuroendocrine differentiation in various tumors. In ALZHEIMER DISEASE and other dementing disorders, there is an important synapse loss due in part to a decrease of synaptophysin in the presynaptic vesicles.

An acidic protein found in the NEUROENDOCRINE SYSTEM that functions as a molecular chaperone for PROPROTEIN CONVERTASE 2.

More From BioPortfolio on "Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas"

Quick Search

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Searches Linking to this Trial